Key points are not available for this paper at this time.
Background: Trial-level meta-analysis to investigate differences in immune-related adverse event (irAE) profiles between anti-PD-1/PD-L1 antibodies. Materials however, findings are hypothesis-generating.
Sonpavde et al. (Tue,) studied this question.